The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases

Abstract

Local therapies offer clear benefit to patients with pulmonary metastatic disease, and a multidisciplinary approach should be used to establish individualized treatment decisions.

Reply from author: What is the right answer for pulmonary metastatic disease? More clinical trials

“… 1 , 2 We applaud these investigators for their conduct of this trial, their thoughtful analyses of their findings, and their dissemination of their outcomes. Moreover, we greatly appreciate their contemplative and informative reply 3 to our publication 4 in the Journal .…”

The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) burden of care study: Analysis of local treatments for lung metastases and systemic chemotherapy in 220 patients in the PulMiCC cohort

“…Since the publication of PulMiCC, commentators have shifted their emphasis towards local control of metastatic disease, including other ablative treatments, repeated interventions and chemotherapy [9,10]. This includes the concept that lung metastasectomy spares patients the side effects of systemic treatments by providing a chemotherapy 'holiday' [11].…”

Commentary: A final episode in the first trilogy

“…Finally, in this issue of the Journal, Antonoff and coworkers 3 have provided the most recent landmark publication in review form of local therapies for pulmonary metastatic disease, with inclusion of the more recent modalities of stereotactic radiation and percutaneous ablation in addition to the surgical standard.…”